Table 3 |
||||||
|
Summary of results from studies of first-line therapy with octreotide LAR in patients with acromegaly |
||||||
|
Reference |
No of pts |
Duration of treatment |
Patients meeting criterion for GH control (%) |
Patients with IGF-1 normalization (%) |
Mean tumor shrinkage (%) |
% of patients with significant tumor shrinkage (definition of significant) |
|
|
||||||
|
Colao et al 2001 [101] |
15 |
12-24 months |
73 |
53 |
53 |
80 (>20%) |
|
Amato et al 2002 [99] |
8 |
24 months |
50 |
50 |
34.8 |
100 (>10%) |
|
Ayuk et al 2004 [100] |
25 |
48 weeks |
62 |
64 |
NR |
NR |
|
Jallad et al 2005 [105] |
28 |
6-24 months |
NR |
43 |
NR |
76 (>25%) |
|
Colao et al 2006 [102] |
34 |
6 months |
61 |
45.5 |
54 (median) |
74 (>30%) |
|
Cozzi et al 2006 [104] |
67 |
6-108 months |
69 |
70 |
62 |
82 (>25%) |
|
Mercado et al 2007 [106] |
68 |
48 weeks |
44 |
34 |
39 |
75 (>20%) |
|
Colao et al 2007 [103] |
56 |
24 months |
86 |
84 |
68 |
NR |
|
Colao et al 2008 [127] |
67 |
12 months |
52 |
58 |
49 |
85 (>25%) |
|
Colao et al 2008 [128] |
40 |
48 weeks |
NR |
NR |
35 |
73 (>20%) |
|
|
||||||
|
NR = not reported |
||||||
|
Biller et al. BMC Endocrine Disorders 2010 10:10 doi:10.1186/1472-6823-10-10 |
||||||
